DMN:FRA
Diamyd Medical AB
0,069 €
arrow_downward
-0,29%(-0,00020) 1D
6 նոյ, 08:02:50 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
146,95 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
146,95 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
Yahoo Finance
·
1 ժամ առաջ
What SPDR S&P 500 ETF (SPY) Sold: Apple Leads on Wednesday
TradingView
·
1 ժամ առաջ
Stock Market Today: Dow Jones, S&P 500 Futures Trade Mixed Ahead of October's Jobs Report— Airbnb, Cloudflare, Lam Research in Focus
Yahoo Finance
·
1 ժամ առաջ
iShares Core S&P 500 (IVV) Buys $394.7 Million More Oracle on Nov. 4
MarketForces Africa
·
2 ժամ առաջ
Global Markets Tumble On Tech Stocks Rout, Nasdaq, S&P 500 Fall
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB